Biosimilars – Advocacy
The Patient Protection and Affordable Care Act (ACA) established a new regulatory pathway for a class of drugs known as biosimilars. Biosimilars, also known as “follow on biologics,” are medicines that are similar to, but not exact copies of, biologically derived drugs. Biologically derived drugs are called